Ads
related to: sanofi
Search results
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.
Market Watch· 8 hours agoFrench pharmaceutical company Sanofi said that the priority review date in the U.S. for its chronic obstructive pulmonary disease treatment, Dupixent has been extended, but ...
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
Reuters via AOL· 8 hours agoFrench drugmaker Sanofi and its U.S. partner have been counting on expanding the use of the drug as...
Sanofi’s Chronic Lung Disease Drug Gets EU Regulator Backing
Bloomberg· 8 hours agoSanofi’s Dupixent is close to being approved in Europe for use in helping patients with a chronic...
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease - Regeneron...
Benzinga· 30 minutes agoOn Friday, the FDA extended the target action date of priority review of supplemental application...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 hours agoNow in its 10th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to secure that employees benefit from the company growth and success ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 8 hours agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of ...
Sanofi’s CEO is giving OpenAI access to its data in the hope of developing drugs more quickly
Fortune via AOL· 2 days agoGood morning from Geneva. If generative AI is going to be more than hype and hallucinations, the...
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
Zacks via Yahoo Finance· 4 days agoThe FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for...
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Zacks via Yahoo Finance· 2 days agoData from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes...
FDA accepts Sanofi’s Sarclisa sBLA for priority review
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe US Food and Drug Administration (FDA) has accepted for priority review Sanofi's supplemental...